Compare Snap Inc (SNAP) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Snap Inc vs Zoetis Inc — how do they compare? Snap Inc trades at $5.51 (market cap $9.05B), while Zoetis Inc trades at $75.23 (market cap $30.92B). The key difference: Zoetis Inc is far larger — about 3.4× Snap Inc's market cap, and Zoetis Inc pays a 2.83% dividend while Snap Inc pays none. Which is the better fit depends on your goals.
| SNAP | ZTS | |
|---|---|---|
Market Cap | $9.05B | $30.92B |
Sector | Media | Health |
52-Week High | $9.09 | $156.76 |
52-Week Low | $3.93 | $71.91 |
Enterprise Value | $10.61B | $38.49B |
Dividend Yield | — | 2.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SNAP trades at $5.33, up 2.3% today, with a bullish technical signal and recent Q2 2026 earnings beating expectations. Revenue grew 19% year-over-year to $1.60 billion, and adjusted EBITDA surged 505%. The stock shows improving operational trends but remains unprofitable, with a net income margin of -4.9% for 2025. Analyst consensus price target is $7.02, suggesting potential upside from current levels.
Outlook hinges on sustained advertising recovery and cost discipline. Risks include persistent losses, high debt, and competitive pressure. Institutional sentiment is mixed, with 38% buy ratings but recent insider selling. The stock offers speculative growth potential if profitability improves, but volatility may persist near-term.
Zoetis (ZTS) trades at $72.66, down 5.92% amid a bearish technical signal and recent earnings pressure. The stock is near its 52-week low after Piper Sandler cut its price target to $80.00 on August 11, 2026. Despite strong profitability with a net margin of 27.69% and ROE of 64.91%, Q2 2026 revenue missed estimates, and the company reduced its 2026 outlook due to softer pet healthcare demand. Cash flow improved in 2025 with net cash flow of $325 million, but debt-to-asset ratio remains elevated at 46.14%.
The outlook is cautious with near-term headwinds in companion animal markets, but long-term fundamentals remain solid given the company's leading position in animal health. Risks include competitive pressures and a class action lawsuit. Analyst consensus is a Buy with a $95.00 price target, implying significant upside if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Snap Inc
Snap, which refers to itself as a camera company, has one of the most popular social networking apps, Snapchat, in developed regions such as North America and Europe. The firm has approximately 158 million daily active users. Snap generates nearly all of its revenue from advertising with 88% coming from the U.S. The firm is headquartered in Venice, California.
Read more on SNAP →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
